TUCUVI

Tucuvi is a clinical voice AI company founded in Madrid in 2019 by biomedical engineers Maria Gonzalez Manso and Marcos Rubio. Its product is not a chatbot bolted onto a hospital website. It is an AI care management platform, and its central agent, LOLA, autonomously conducts patient phone conversations, executes clinical and care-coordination workflows, and escalates higher-risk cases to human teams when they need attention.

The problem Tucuvi set out to solve is one every health system recognizes: there are not enough clinicians to keep up with the follow-up work. Discharge a patient after surgery, and someone should call to check on them. Manage a population with chronic obstructive pulmonary disease, and someone should track symptoms before they turn into a readmission. In practice, those calls often do not happen - not because they do not matter, but because a finite number of nurses cannot dial an infinite number of patients.

Tucuvi's bet is that this is a capacity problem, not a demand problem, and that a well-designed AI agent can lift the ceiling on how much a care team can do without lowering the floor of quality. LOLA speaks with patients in their own language, follows validated clinical protocols, listens for warning signs, and connects a clinician when the conversation warrants it. The company reports that the agent reaches more than 90% of even high-complexity, elderly populations - groups often assumed too difficult to engage by phone.

What separates Tucuvi from the crowded field of healthcare AI is less about the model and more about the paperwork. In early 2026 the company became the first AI platform to receive European Class IIb Software as a Medical Device certification for both its voice agent and its care management platform. That is a regulatory bar usually reserved for physical equipment like infusion pumps, and clearing it is slow, expensive work. It is also, arguably, the point. In a market flooded with unregulated assistants, certification is the difference between a demo and a device a hospital can put in front of patients.

The results the company cites are specific rather than sweeping. Up to 80% of nursing follow-up workflows automated. Patient reach and engagement above 90% across complex populations. A 5.5% reduction in COPD readmissions at partner health systems. These are the kinds of numbers that matter to a hospital operations director deciding whether to trust an algorithm with a patient call.

Behind the company is a founder story that shapes its priorities. Maria Gonzalez Manso, trained as a biomedical engineer, has spoken about losing her mother after a reported hospital administration error - the sort of gap in follow-through that a system stretched too thin can produce. That history helps explain why Tucuvi chose the harder, safety-first path of certification and escalation logic rather than the faster path of an unregulated consumer tool.

The customer list has grown accordingly. More than 60 healthcare organizations across Europe, the UK and the US use the platform, including over 10% of Spain's public hospitals, parts of the UK's National Health Service, and leading institutions such as Vall d'Hebron. Pharmaceutical partner AstraZeneca uses the platform for heart-failure monitoring. Across all of them, LOLA has now held more than a million patient conversations.

In January 2026 Tucuvi raised a $20 million Series A - roughly 17 million euros - led by Cathay Innovation and Kfund, with participation from existing backers Frontline Ventures, Seaya Ventures and Shilling. The company said the money would accelerate its go-to-market push across Europe and the US, expand its agentic AI capabilities, and continue evolving the platform into what it calls a system of action and intelligence for care teams. A New York office signals the direction of travel.

The framing Tucuvi uses is augmentation, not replacement. LOLA does not fire the nurse; it calls the 400 patients the nurse never had time to reach and surfaces the 40 who need a human. That distinction - between doing the work and expanding who can be reached - is where the company stakes its claim in a market that is only getting more crowded, and more scrutinized.